Helixmith Co., Ltd.
KKRX:0849903,905.00
KRW
+10.00
(+0.26%)
ISIN
KR7084990001
Return %
Stock
S&P 500
1Y
-27.95
14.39
3Y
-4.64
81.42
5Y
-82.29
68.62
Capital Structure
KRW
•
in mil. unless spec.Working Capital
KRW
•
in mil. unless spec.Growth Rates
KRW
•
in mil. unless spec.Quarterly Revenue
KRW
•
in mil. unless spec.Quarterly Earnings Per Share
KRW
•
in mil. unless spec.Quarterly Dividends Per Share
KRW
•
in mil. unless spec.Company Description
- CEO
- Song-Sun Chang
- Full Time Employees
- 44
- Sector
- Health technology
- Industry
- Biotechnology
- Address
- Building 203 Seoul SL South Korea 151-747
- IPO Date
- Dec 29, 2005
- Website
- helixmith.com
- Similar Companies
- Business
- Helixmith Co., Ltd. (KOSDAQ: 084990) is a clinical-stage biotechnology company focused on developing gene therapies, biologics, antibodies, and phytotherapeutics for neuromuscular, ischemic, and chronic diseases. The company offers core products including Engensis (VM202), a non-viral plasmid DNA encoding hepatocyte growth factor (HGF) isoforms for diabetic peripheral neuropathy (phase III), diabetic foot ulcers (phase III), amyotrophic lateral sclerosis (phase II), claudication (phase II), coronary artery disease (phase II), and Charcot-Marie-Tooth disease (phase I/IIa); VM507, an antibody activating c-MET for chronic kidney disease (preclinical); nutraceuticals such as LAYLA Tab (PG201) for osteoarthritis, Allex and Allex i for hypersensitivity improvement, and Mnemosyne for memory improvement; and pipeline candidates including NM101 for peripheral neuropathy, NM301 for ALS, NM302, HX204 for inflammatory bowel disease, HX109 for prostate health, HX110 for respiratory health, and HX112 for women's climacteric health. It also advances CAR-T cell therapies via subsidiary Cartexell for solid tumors (preclinical) and AAV gene therapies for neuromuscular diseases like ALS and multiple sclerosis. Helixmith operates primarily in South Korea and the United States, with target markets encompassing patients with diabetic complications, neurodegenerative disorders, cardiovascular conditions, and chronic inflammatory diseases; its nutraceuticals serve domestic health functional food consumers. Founded in November 1996 as the first on-campus startup at Seoul National University (formerly ViroMed Co., Ltd. until its April 2019 name change and headquarters relocation to Magok, Seoul), the company maintains its primary base at 21 Magokjungang 8-ro 7-gil, Gangseo-gu, Seoul, South Korea, with a U.S. presence in San Diego, California. Recent developments include ongoing phase III trials for donaperminogene seltoplasmid (VM202) in diabetic peripheral neuropathic pain initiated in 2021, positioning it for potential near-term commercialization in China as highlighted in 2025 market updates, and preclinical-to-phase I advancements in AAV and antibody programs for ALS with planned studies between 2024 and 2026. The company continues to leverage its RMAT designation from the U.S. FDA for VM202 in diabetic peripheral neuropathy (granted 2018), alongside orphan drug and fast track statuses for ALS indications, supporting expanded clinical activities without reported new partnerships, acquisitions, or funding rounds in the past 1-2 years.